Clinical Trials Logo
  1. Home
  2. Plaque
  3. NCT02635789

Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)

Plaque Clinical Trial

Official title:
A Double-blind, Randomized, Placebo-controlled Phase III Trial to Investigate the Efficacy and Safety of NPC-12G Gel (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex

Clinical Trial Summary

The purpose of this trial is to evaluate the efficacy and safety of NPC-12G gel (topical formulation of sirolimus) versus placebo gel to facial angiofibroma and other skin lesions in patients with tuberous sclerosis complex (TSC)

Clinical Trial Description

Tuberous Sclerosis Complex (TSC) is an autosomal dominant hereditary disease that causes benign tumors on the almost whole body (including skin, brain, kidney, lung and heart), behavior disorder as autism, mental retardation and neurologic symptom as epilepsy. Angiofibroma is TSC-specific facial skin lesions, and hamartoma caused by increase of the component of skin connective tissues and blood vessels. Other skin lesions due to TSC are white macule(hypomelanotic macule), plaque, shagreen patch and ungual fibromas. Current therapeutic methods for angiofibroma are laser or surgical treatments, but there are problems as many relapses, deficiency of evidence, change of pigment, scar and risk of infection.

This will be a multicenter, double-blind, randomized, placebo-controlled parallel group trial. The trial has three phases; the screening phase, double-blinded treatment phase, and post-treatment phase. The screening phase comprises a screening visit where subject's initial eligibility will be evaluated. During double-blinded treatment phase, patients who meet all entry criteria for the trial will be randomized into two groups, and they will apply 0.2% NPC-12G gel or placebo gel topically twice a day for 12 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02635789
Study type Interventional
Source Nobelpharma
Contact
Status Completed
Phase Phase 3
Start date December 2015
Completion date October 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT02980497 - Antiplaque/Antigingivitis Efficacy of Essential Oil Mouthrinses in Six-Month Study N/A
Completed NCT02377310 - Pd/Pa vs iFR™ in an Unselected Population Referred for Invasive Angiography N/A
Not yet recruiting NCT03877705 - Xylitol Chewable Tablets Versus Xylitol Chewing Gum in Geriatric Bedridden Patients Early Phase 1
Completed NCT02666508 - Trial of Toothpaste to Reduce Plaque and Inflammation N/A
Completed NCT04921371 - Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque Phase 1
Completed NCT05138978 - Metagenomic and Metatranscriptomic Analysis of Clinical Plaque Samples Phase 2
Completed NCT05428189 - Efficacy of the Disclosing Plaque Agent as a Guide to Remove the Oral Biofilm in Orthodontic Patients. N/A
Completed NCT05091216 - The Effects of Traditional Chinese Medicine Mouthwash Solutions on the Oral Health of Leprosy Patients N/A
Not yet recruiting NCT05031260 - COMORAL® the Oral Irrigation Unit Clinical Trial N/A
Active, not recruiting NCT03022344 - DD2-Coronary Plaque Morphology and Plaque Progression N/A
Completed NCT05121909 - A Study of Experimental Mouthwashes Phase 4
Completed NCT06318819 - Plaque Removal Effectiveness of a Flossing Device Compared to the Conventional Flossing in Adults N/A
Completed NCT03989427 - The Effectiveness of Brushing and Flossing Sequence on Control of Plaque and Gingival Inflammation N/A
Completed NCT04407208 - Convalescent Plasma Therapy in Patients With COVID-19 Phase 1
Completed NCT05821712 - A New Mouthwash on Reducing Dental Plaque and Helping Prevent Gum Problems Phase 3
Completed NCT05239351 - Evaluating Performance and Safety of the Medical Device Jalucomplex in the Treatment of Facial and Neck Tissue Defects N/A
Active, not recruiting NCT05239117 - Evaluating the Performance and Safety of the Medical Device Plenhyage® in the Treatment of Dermal Tissue Defects N/A
Completed NCT05120141 - A Twelve Week Study of Experimental Mouth Rinses Phase 4
Active, not recruiting NCT05239130 - Evaluating the Performance and Safety of the Medical Device Auralya® in the Treatment of Facial Dermal Tissue Defects N/A
Completed NCT05239156 - Evaluating the Performance and Safety of the Medical Device Janesse in the Treatment of Facial Dermal Tissue Defects N/A